参考文献

[1]Chen W,Sun K,Zheng R,et al. Cancer incidence and mortality in China,2014.Chin J Cancer Res,2018,30(1):1-12.
[2]Chen X,Li Y,Ouyang T,et al. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.Ann Oncol,2018,29(10):2046-2051.
[3]Fan C,Zhang J,Ouyang T,et al. RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients. Int J Cancer,2018,143(8):1935-1942.
[4]Zhang J,Lin Y,Sun X J,et al. Biomarker assessment of the CBCSG006 trial:a randomized phase Ⅲtrial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol,2018,29(8):1741-1747.
[5]Chen L,Yang L,Yao L,et al. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun,2018,9(1):1357.
[6]Liu XY,Ma D,Xu XE,et al. Genomic landscape and endocrine-resistant subgroup in estrogen receptor-positive,progesterone receptor-negative,and HER2-negative breast cancer.Theranostics,2018,8(22):6386-6399.
[7]Li H,Liu J,Chen J,et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat Commun,2018,9(1):1614.
[8]Sun C,Yang F,Zhang Y,et al. tRNA-Derived fragments as novel predictive biomarkers for trastuzumabresistant breast cancer. Cell Physiol Biochem,2018,49(2):419-431.
[9]Lan B,Ma F,Zhai X,et al. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. Int J Cancer,2018,143(1):184-189.
[10]Lan B,Ma F,Chen S,et al. Toremifene,rather than tamoxifen,might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. Int J Cancer,2018,143(10):2499-2504.
[11]Zhu Y,Liu Y,Zhang C,et al.Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.Nat Commun,2018,9(1):1595.
[12]Tong Y,Chen X,Fei X,et al. Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?Eur J Cancer,2018,89:9-18.
[13]Chow L,Morita S,Chow C,et al. Neoadjuvant palbociclib on ER+ breast cancer(N007):clinical response and EndoPredict's value.Endocr Relat Cancer,2018,25(2):123-130.
[14]Zhang Y,Ji Y,Li J,et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist(GnRHa)among estrogen receptor(ER)-positive premenopausal breast cancer patients:effects on ovarian function,disease-free survival,and overall survival,Breast Cancer Res Treat,2018,168(3):679-686.
[15]Chen J,Yao Q,Huang M,et al. A randomized Phase Ⅲ trial of neoadjuvant recombinant human endostatin,docetaxel and epirubicin as first-line therapy for patients with breast cancer(CBCRT01). Int J Cancer,2018,142(10):2130-2138.
[16]Wu X,Tang P,Li S,et al. A randomized and open-label phase Ⅱ trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.Nat Commun,2018,9(1):832.
[17]Gong C,Ma G,Hu X,et al. Pretreatment(18)F-FDG uptake heterogeneity predicts treatment outcome of first-line chemotherapy in patients with metastatic triple-negative breast cancer. Oncologist,2018,23(10):1144-1152.
[18]Wang X,Ma J,Mei X,et al. Outcomes following salvage radiation and systemic therapy for isolated locoregionalrecurrence of breast cancer after mastectomy:impact of constructed biologic subtype. J Oncol,2018,2018:4736263.
[19]Zhu Q,Kirova Y M,Cao L,et al.Cardiotoxicity associated with radiotherapy in breast cancer:A question-based review with current literatures. Cancer Treat Rev,2018,68:9-15.
[20]Wang J,Zhou F,Li Z,et al. Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis. Sci Rep,2018,8(1):998.
[21]Mu J,Xi D,Ding Y,et al. Chair heterogeneity index:describing the dose heterogeneity inside the tumor volume where there is a boost volume.Sci Rep,2018,8(1):9763.
[22]Yu T,Xu M,Sun T,et al.External-beam partial breast irradiation in a supine versus prone position after breast-conserving surgery for Chinese breast cancer patients. Sci Rep,2018,8(1):15354.
[23]Wu SG,Zhang WW,Sun J Y,et al. Omission of postoperative radiotherapy in women aged 65 years or older with tubular carcinoma of the breast after breast-conserving surgery. Front Oncol,2018,8:190.
[24]Yuan L. et al. Comparison of sentinel lymph node detection performances using blue dye in conjunction with indocyanine green or radioisotope in breast cancer patients:a prospective single-center randomized study.Cancer Biol Med,2018,15(4):452-460.
[25]Shen S. et al. Comparison of sentinel lymph node biopsy guided by blue dye with or without indocyanine green in early breast cancer. J Surg Oncol,2018,117(8):1841-1847.
[26]Maimaitiaili A.,et al. Analysis of factors related to non-sentinel lymph node metastasis in 296 sentinel lymph node-positive Chinese breast cancer patients. Cancer Biol Med,2018,15(3):282-289.
[27]Wu S. et al. Intraoperative touch imprint cytology in targeted axillary dissection after neoadjuvant chemotherapy for breast cancer patients with initial axillary metastasis. Ann SurgOncol,2018,25(11):3150-3157.
[28]Huang NS. et al. Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy. Cancer Med,2018,7(1):56-63.
[29]Xie X,et al. Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer. Int J Cancer,2018,142(9):1901-1910.
[30]Qi XW,et al. Clinical significance of internal mammary lymph node metastasis for breast cancer:Analysis of 337 breast cancer patients. Surg Oncol,2018,27(2):185-191.
[31]Wang K,et al. Predictors of internal mammary lymph nodes(IMLN)metastasis and disease-free survival comparison between IMLN-positive and IMLN-negative breast cancer patients:Results from Western China Clinical Cooperation Group(WCCCG)database(CONSORT). Medicine(Baltimore),2018,97(28):e11296.
[32]Xiong Z,et al. Could local surgery improve survival in de novo stage Ⅳ breast cancer?BMC Cancer,2018,18(1):885.
[33]Xiong Z,et al. Patterns of occurrence and outcomes of contralateral breast cancer:Analysis of SEER Data. J Clin Med,2018. 7(6).
[34]Wang,J. et al. The Distribution and outcomes of the 21-Gene recurrence score in T1-T2N0 estrogen receptorpositive breast cancer with different histologicsubtypes. Front Genet,2018,9:638.
[35]Lei,Y.Y. et al. Adherence to the World Cancer Research Fund/American Institute for Cancer Research Guideline Is associated with better health-related quality of life among chinese patients with breast cancer. J Natl Compr Canc Netw,2018,16(3):275-285.
[36]Cui,L. et al. Single institution analysis of incidence and risk factors for post-mastectomy pain syndrome. Sci Rep,2018,8(1):11494.
[37]Li,W. et al. Precise pathologic diagnosis and individualized treatment improve the outcomes of invasive micropapillary carcinoma of the breast:a 12-year prospective clinical study. Mod Pathol,2018,31(6):956-964.